This is a news story, published by Investor's Business Daily, that relates primarily to Moderna news.
For more Moderna news, you can click here:
more Moderna newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Moderna stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Moderna news, respiratory market news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mResviaInvestor's Business Daily
•
82% Informative
Moderna 's mResvia generated just $10 million in sales in its first quarter on the market.
The company kept its outlook for the year at $3 billion to $3.5 billion in sales.
Moderna stock jumped 6.5% to 55.15 in premarket action.
Company slashed its research and development budget for 2027 , issued a light 2025 outlook.
VR Score
88
Informative language
92
Neutral language
5
Article tone
semi-formal
Language
English
Language complexity
35
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links